Product Highlight - Tabrecta

17 Jun 2022
Product Highlight - Tabrecta
Active ingredient: Capmatinib.

Indication: Adults w/ metastatic non-small cell lung cancer (NSCLC) w/ a MET exon 14 skipping mutation.

Dosage & Administration: Recommended dose: 400 mg PO bid w/ or w/o food.

Related MIMS Drugs

Editor's Recommendations